Last updated on June 2019

Buprenorphine to Improve HIV Care Engagement and Outcomes (BRAVO)


Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: AIDS Vaccines | HIV positive | Drug abuse | HIV | HIV infection
  • Age: Between 18 - 100 Years
  • Gender: Male or Female

Inclusion Criteria:

  • HIV positive
  • Current moderate or severe DSM-V opioid use disorder
  • Urine drug screen positive for opioids
  • Interested in receiving treatment for opioid dependence
  • Age at least 18 years old
  • Willing to practice an effective method of birth control, if female

Exclusion Criteria:

  • Known hypersensitivity to buprenorphine or naloxone
  • AST & ALT > 5x upper limit
  • Currently pregnant or breastfeeding
  • Serious medical or psychiatric illness in past 30 days (e.g. opportunistic infection, psychosis) that precludes safe participation in the opinion of study physician
  • Methadone maintenance treatment within 30 days of consent

Recruitment Status: Closed


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.